Profile data is unavailable for this security.
About the company
TSUMURA & CO. is a Japan-based company mainly engaged in the manufacture and sale of ethical and general pharmaceuticals. Through its subsidiaries, the Company is also engaged in the procurement, sorting and processing of crude drugs, the manufacture and sale of Chinese herbal extract powders and drug substances, the operation of dispensing pharmacies and the provision of logistics services, as well as the development of pharmaceuticals.
- Revenue in JPY (TTM)148.79bn
- Net income in JPY16.76bn
- Incorporated1936
- Employees4.03k
- LocationTsumura & Co2-17-11, AkasakaMINATO-KU 107-8521JapanJPN
- Phone+81 363617200
- Websitehttps://www.tsumura.co.jp/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Towa Pharmaceutical Co Ltd | 236.78bn | 11.74bn | 143.01bn | 4.30k | 11.64 | 0.9181 | 4.48 | 0.604 | 238.42 | 238.42 | 4,810.52 | 3,023.62 | 0.6134 | 1.62 | 3.73 | 55,090,510.00 | 3.04 | 4.73 | 3.80 | 6.39 | 34.66 | 41.27 | 4.96 | 8.06 | 1.48 | -- | 0.5686 | 19.97 | 26.11 | 17.46 | -86.17 | -19.46 | 14.66 | 13.63 |
| KAKEN PHARMACEUTICAL CO., LTD. | 72.10bn | 2.97bn | 155.69bn | 1.13k | 43.37 | 0.9158 | 27.23 | 2.16 | 78.14 | 78.14 | 1,915.49 | 3,700.49 | 0.429 | 1.86 | 2.89 | 63,801,770.00 | 1.76 | 8.17 | 2.00 | 9.56 | 53.89 | 55.55 | 4.11 | 16.09 | 4.68 | -- | 0.0267 | 44.04 | -4.01 | -5.81 | -43.03 | -22.17 | 3.16 | 0.00 |
| Sumitomo Pharma Co Ltd | 330.31bn | -173.72bn | 159.16bn | 6.25k | -- | 0.4626 | -- | 0.4819 | -437.26 | -437.26 | 831.40 | 864.73 | 0.2717 | 1.36 | 2.71 | 52,849,120.00 | -14.95 | 1.15 | -22.20 | 1.67 | 59.93 | 72.18 | -55.04 | 2.54 | 0.3785 | -- | 0.5452 | 41.44 | -0.8019 | 3.54 | -232.08 | -- | 0.6204 | 3.13 |
| Kissei Pharmaceutical Co Ltd | 73.72bn | 12.20bn | 174.32bn | 1.80k | 13.26 | 0.7995 | 10.54 | 2.36 | 266.51 | 266.51 | 1,612.29 | 4,421.72 | 0.3213 | 1.68 | 2.60 | 41,067,970.00 | 5.38 | 3.21 | 5.87 | 3.47 | 48.23 | 52.39 | 16.74 | 11.10 | 4.51 | -- | 0.007 | 36.56 | 3.23 | -1.83 | -18.52 | 3.08 | 3.74 | 10.76 |
| Peptidream Inc | 28.71bn | 3.04bn | 207.43bn | 603.00 | 68.09 | 5.12 | 37.93 | 7.22 | 23.43 | 23.43 | 221.37 | 311.32 | 0.4307 | 4.52 | 2.66 | 47,615,580.00 | 4.55 | -- | 5.34 | -- | 59.97 | -- | 10.57 | -- | 2.88 | 2.80 | 0.3551 | -- | 6.93 | -- | -59.81 | -- | -- | -- |
| Sawai Group Holdings Co Ltd | 185.31bn | 17.71bn | 260.50bn | 3.39k | 14.75 | 1.24 | 8.20 | 1.41 | 403.17 | 348.86 | 4,219.61 | 4,800.54 | 0.4905 | 1.32 | 2.75 | 54,615,090.00 | 3.62 | 1.14 | 5.08 | 1.56 | 30.41 | 36.92 | 7.39 | 2.24 | 1.31 | 71.96 | 0.291 | 81.02 | 3.37 | 3.58 | 144.81 | -2.01 | 10.06 | 0.00 |
| Tsumura & Co | 148.79bn | 16.76bn | 284.01bn | 4.03k | 16.78 | 1.04 | 9.70 | 1.91 | 220.44 | 220.44 | 1,954.80 | 3,569.48 | 0.3633 | 0.7326 | 2.27 | 36,903,020.00 | 4.55 | 4.98 | 5.57 | 6.03 | 47.57 | 53.82 | 12.53 | 12.74 | 2.90 | -- | 0.2115 | 30.98 | 8.10 | 3.51 | -12.50 | 2.59 | 6.41 | 0.00 |
| Nippon Shinyaku Co., Ltd. | 146.98bn | 24.14bn | 302.57bn | 2.19k | 12.02 | 1.35 | 10.36 | 2.06 | 358.40 | 358.40 | 2,182.30 | 3,192.25 | 0.6128 | 1.37 | 2.97 | 67,237,880.00 | 10.07 | 10.41 | 11.44 | 12.28 | 64.60 | 59.11 | 16.43 | 15.84 | 4.49 | -- | 0.0094 | 32.10 | 4.87 | 7.28 | -8.70 | 11.98 | 22.93 | 17.00 |
| Hisamitsu Pharmaceutical Co Inc | 141.71bn | 13.97bn | 315.96bn | 2.77k | 20.50 | 1.06 | 16.12 | 2.23 | 180.93 | 180.93 | 1,840.25 | 3,497.04 | 0.441 | 3.13 | 3.43 | -- | 4.49 | 4.22 | 5.25 | 4.82 | 55.73 | 58.62 | 10.18 | 10.03 | 3.76 | -- | 0.0078 | 52.55 | 10.42 | -0.2385 | 18.97 | -6.17 | 28.90 | 0.5989 |
Data as of Apr 26 2024. Currency figures normalised to Tsumura & Co's reporting currency: Japanese Yen JPY
30.72%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Invesco Asset Management (Japan) Ltd.as of 29 Mar 2024 | 5.83m | 7.60% |
| Marathon Asset Management Ltd.as of 29 Mar 2024 | 5.59m | 7.29% |
| Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 15 Apr 2024 | 2.52m | 3.29% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 2.27m | 2.96% |
| Nomura Asset Management Co., Ltd.as of 29 Mar 2024 | 1.91m | 2.49% |
| Templeton Investment Counsel LLCas of 29 Feb 2024 | 1.20m | 1.57% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 1.20m | 1.57% |
| Baillie Gifford & Co.as of 31 Mar 2024 | 1.20m | 1.57% |
| Nikko Asset Management Co., Ltd.as of 15 Apr 2024 | 938.80k | 1.22% |
| Daiwa Asset Management Co. Ltd.as of 29 Mar 2024 | 889.30k | 1.16% |
More ▼
Data from 31 Dec 2023 - 18 Apr 2024Source: FactSet Research Systems Inc.
